GSK reports better-than-expected Q4 earnings. It also announces a new share buyback program and raises the long-term sales outlook for 2031 by $2 billion.
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics sold by majority-owned joint venture ViiV Healthcare, which helped group ...
Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...
GSK plc GSK reported fourth-quarter 2024 core ... J&J JNJ-partnered Juluca — and long-acting medications, Apretude and Cabenuva. The combined revenues from these four drugs contributed more ...
The pharmaceutical giant is now targeting more than £40billion in annual revenue by 2031, compared to a previous outlook of £38billion.
GSK saw turnover increase by 7 per cent to £31.7billion over the full year, thanks to rising demand for specialty medicines like HIV treatments Dovato and Cabenuva and sales of oncology medicines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback